ATE540695T1 - Verfahren zur modulation von il-13 - Google Patents

Verfahren zur modulation von il-13

Info

Publication number
ATE540695T1
ATE540695T1 AT02749560T AT02749560T ATE540695T1 AT E540695 T1 ATE540695 T1 AT E540695T1 AT 02749560 T AT02749560 T AT 02749560T AT 02749560 T AT02749560 T AT 02749560T AT E540695 T1 ATE540695 T1 AT E540695T1
Authority
AT
Austria
Prior art keywords
modulating
expression
activity
modulates
mammal
Prior art date
Application number
AT02749560T
Other languages
English (en)
Inventor
Yuhong Zhou
Jamila Louahed
Nicholas Nicolaides
Michael Mclane
Roy C Levitt
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ATE540695T1 publication Critical patent/ATE540695T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT02749560T 2001-06-08 2002-06-10 Verfahren zur modulation von il-13 ATE540695T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29719001P 2001-06-08 2001-06-08
PCT/US2002/017881 WO2002100432A1 (en) 2001-06-08 2002-06-10 Methods for the modulation of il-13

Publications (1)

Publication Number Publication Date
ATE540695T1 true ATE540695T1 (de) 2012-01-15

Family

ID=23145234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02749560T ATE540695T1 (de) 2001-06-08 2002-06-10 Verfahren zur modulation von il-13

Country Status (4)

Country Link
US (2) US20040219149A1 (de)
EP (1) EP1401497B1 (de)
AT (1) ATE540695T1 (de)
WO (1) WO2002100432A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
WO2004103295A2 (en) * 2003-05-14 2004-12-02 Bayer Pharmaceuticals Corporation Interleukin-9 antagonist muteins and their pharmacological methods of use
WO2006014953A2 (en) * 2004-07-28 2006-02-09 Ludwig Institute For Cancer Research Method for treatment or prophylaxis of a infection using either an antibody which binds to il-9 or an agent which stimulates production of autoantibodies to interleukin-9
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2008153790A2 (en) * 2007-05-29 2008-12-18 University Of Cincinnati Methods of modulating inflammation and compositions therefore

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4761375A (en) * 1984-05-08 1988-08-02 Genetics Institute, Inc. Human interleukin-2 cDNA sequence
US5208218A (en) 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5587302A (en) 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5580753A (en) 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
AU7552691A (en) 1990-03-23 1991-10-21 GSF-Institut Fur Experimentalle Hamatologie Method for enhanced growth and proliferation of mast cells
US5116951A (en) * 1990-09-19 1992-05-26 Ludwig Institute For Cancer Research Substantially pure interleukin-9 receptor and uses thereof
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
CA2666298A1 (en) * 1995-08-24 1997-03-06 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US5908839A (en) * 1995-08-24 1999-06-01 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Also Published As

Publication number Publication date
EP1401497A1 (de) 2004-03-31
US20090191191A1 (en) 2009-07-30
US7919248B2 (en) 2011-04-05
EP1401497A4 (de) 2006-08-16
WO2002100432A8 (en) 2003-11-20
WO2002100432A1 (en) 2002-12-19
US20040219149A1 (en) 2004-11-04
EP1401497B1 (de) 2012-01-11

Similar Documents

Publication Publication Date Title
ATE420947T1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
DE60123055D1 (de) Verfahren zur behandlung von entzündungsbedingten zuständen der augen
EP1324780A4 (de) Methoden zur behandlung von herzarrhythmie
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE480253T1 (de) Verwendung von botulinum toxin zur behandlung von gelenkschmerzen
DE60116339D1 (de) Waschkit sowie verfahren zur kombinierten pflege und reinigung von gewebe
ATE419869T1 (de) Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
ATE266397T1 (de) Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE466582T1 (de) 16-phenoxy-lipoxin analoge zur medizinischen verwendung
ATE334682T1 (de) Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60006675D1 (de) Verfahren zur verbesserung der fertilisierenden aktivität von spermatozoa
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE333279T1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
ATE452906T1 (de) Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
EP1401497A4 (de) Verfahren zur modulation von il-13
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE271885T1 (de) Verfahren zur begasung von geschlossenen systemen
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat